Skip to content

18-158 - Determining the Maximum Tolerated Dose and/or the Minimum Tolerated Dose of Dual Experimental Study Drug for Treatment of Newly Diagnosed Ovarian Cancer (OVATION 2)

Status: open

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Treatment for Ovarian Cancer

Contact Us


This dose escalation study will determine a maximum tolerated dose and/or optimal biological dose of GEN-1 for carboplatin/paclitaxel combination in newly diagnosed ovarian cancer. IRB Number 18-158

Providers Associated With This Trial

Principle Investigator

  • New pic of dr scaliciView Profile
    Jennifer M. Scalici, M.D.Gynecologic OncologistChief of Gynecologic Oncology Service; Professor of Interdisciplinary Clinical Oncology; Director of Gynecologic Oncology Research Laboratory
This link will open in a new tab or window.